Description of Skin Lesion/ Outcome Lenalidomide stopped permanently N/Sex/Age, y Disease Study Design Reference
Sweet Syndrome of the hands on day 6 after initiation of treatment with lenalidomide.  Oral prednisolone 40mg was given and tapered over several weeks. yes 1/M/57 MM Case Report Hoverson AR et al. 2006
Granulomatous dermatitis on the trunk and extremities. The skin eruptions resolved.  yes 1/F/55 MM Case Report Deng A et al. 2006
Neutrophilic dermatosis on day 14 after treatment initiation. Clinical improvement after discontinuation of lenalidomide and initiation of oral prednisolone. yes 1/F/57 MM Case Report Thieu KP et al. 2009
Acneiform lesions of the head and neck with the finding of Candida albicans at the end of the 3rd treatment cycle.  Lesions resolved 3 months after lenalidomide cessation and treatment with topical desonide and oral doxycycline. yes 1/M/75 MM Case Report Michot C et al. 2010
Mildly pruritic truncal eruption within the 1st week after treatment initiation with lenalidomide for MM. Treatment was discontinued because of edema, fatigue, dizziness, gastritis and this skin eruption. 2 months later AM was diagnosed and a combination treatment with lenalidomide, dexamethasone, and melphalan begun. Purpuric skin eruptions appeared within 1 week of combination treatment. yes 1/M/74 AM and MM Case Report Kuohung et al. 2011
Blaschkitis along the left leg, the trunk and the left arm in the 4th month after treatment initiation. Disappearance of eruptions during drug-free intervals and reappearance after restart of treatment. no 1/M/60 MM Case Report Grape J et al.. 2011
Macular skin eruptions evolving to SJS after the end of the 1st treatment cycle.  A symptomatic treatment with methylprednisolone, itraconazole, antihistamines and antiseptics was initiated. Skin lesions resolved after 30 days. yes 1/F/69 MM Case Report Allegra A et al. 2012
3 patients developed skin reactions, 1 urticaria, 1 EM, 1 SJS. x 2/F/70, 81        
1/M/62
MM Case Reports Penna G et al. 2012
SJS/TEN overlap appearing during the 2nd treatment cycle. Discontinuation of lenalidomide, systemic corticosteroids and intensive supportive care led to clinical recovery. yes 1/M/61 MM Case Report Wäsch R et al.. 2012
Skin eruptions progressing to SJS beginning on day 24 of the 1st  treatment cycle. Progress of symptoms after initiation of prednisolone and antihistamines. Recovery under corticosteroids, high dose IVIG, prophylactic antibiotics and fluid input. yes 1/M/51 PCL Case Report Siniscalchi A et al. 2012
12 reports of SJS, 3 reports of EM, 1 report of TEN. The median time of onset of event was 24 days (3-45) from start of lenalidomide. x 7/F, 5/M 
(median 63,5; 50-83)
MM
MF 
AM
Case Reports from market launch 12/2005-06/2008) Castaneda CP et al. 2009
Skin eruption were described as morbilliform (N=22), urticarial (N=6), dermatitic (N=2), acneiform (N=1) and undefined (N=1). x 22/x/x
10/x/x
MM
AM
Retrospective review of medical records Sviggum HP et al. 2006
Abbreviations: AM: Amyloidosis; EM: Erythema Multiforme; F: Female; IVIG: Intravenous Immunoglobulins; M: Male; MF: Myelofibrosis; MM: Multiple Myeloma; N: Number of Patients; PCL: Primary Plasma Cell Leukemia; SJS: Stevens-Johnson Syndrome; TEN: Toxic Epidermal Necrolysis; x: Not Listed; y: Years
Table 1: Reported adverse skin events in patients treated with lenalidomide.
Goto home»